Chemistry:Trevogrumab
From HandWiki
Trevogrumab (INN;[1] development code REGN1033) is a human monoclonal antibody designed for the treatment of muscle atrophy due to orthopedic disuse and sarcopenia. It is often used with Garetosmab.
Trevogrumab is a fully human monoclonal antibody that functions as a selective inhibitor of myostatin (GDF8), a key negative regulator of skeletal muscle growth and mass. By binding and neutralizing myostatin, Trevogrumab prevents its interaction with activin type 2 receptors (ActRIIA/B), thereby reducing myostatin-mediated signaling and allowing increased muscle growth and preservation.[2]
This drug was developed by Regeneron Pharmaceuticals, Inc.[3]
References
- ↑ World Health Organization (2015). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 113". WHO Drug Information 29 (2). https://www.who.int/medicines/publications/druginformation/innlists/PL113.pdf.
- ↑ "GDF8 and activin A blockade protects against GLP-1-induced muscle loss while enhancing fat loss in obese male mice and non-human primates". Nature Communications 16 (1). May 2025. doi:10.1038/s41467-025-59485-9. PMID 40360507. Bibcode: 2025NatCo..16.4377M.
- ↑ "Trevogrumab". Statement On A Nonproprietary Name Adopted By The USAN Council. American Medical Association. https://searchusan.ama-assn.org/undefined/documentDownload?uri=%2Funstructured%2Fbinary%2Fusan%2Ftrevogrumab.pdf.
 |  |
